MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Chemotherapy

Empirical model of mesothelioma potency factors for different mineral fibers based on their chemical composition and dimensionality.

Inhalation Toxicology 2019 April [Link] Korchevskiy A, Rasmuson JO, Rasmuson EJ Abstract Context: The potency of various mineral fiber types to produce mesothelioma was previously evaluated for numerous cohorts, but the differences in potencies for distinct fiber types have yet to be explained. Objective: To develop an empirical model that would reconstruct mesothelioma potency factors for various types […]

Comments Off on Empirical model of mesothelioma potency factors for different mineral fibers based on their chemical composition and dimensionality.

Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.

European Journal of Pharmaceutical Sciences 2019 July 11 [Link] Amano Y, Ohta S, Sakura KL, Ito T Abstract Pemetrexed (PMX) is a multi-targeted antifolate drug used for the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer. Hyaluronan (HA) in blood is well known as a disease marker of MPM. We synthesized PMX-conjugated […]

Comments Off on Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.

Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.

Journal of Thoracic Disease 2019 May [Link] Klotz LV, Lindner M, Eichhorn ME, Grützner U, Koch I, Winter H, Kauke T, Duell T, Hatz RA Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with few long-term survivors. Despite the dismal prognosis, hyperthermic intrathoracic chemoperfusion (HITHOC) was shown to improve survival in a selective […]

Comments Off on Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma.

Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.

Japanese Journal of Clinical Oncology 2019 July 9 [Link] Nagata Y, Sawada R, Takashima A, Shoji H, Honma Y, Iwasa S, Amano K, Kato K, Hamaguchi T, Shimada Y, Saruta M, Boku N Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare cancer for which no standard systemic chemotherapy has been established. While cisplatin plus […]

Comments Off on Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma.

What can independent research for mesothelioma achieve to treat this orphan disease?

Expert Opinion on Investigational Drugs 2019 July 1 [Link] Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, Mutti L Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor prognosis, as current therapies are ineffective. Despite the increased understanding of the molecular biology of mesothelioma, there is still […]

Comments Off on What can independent research for mesothelioma achieve to treat this orphan disease?

Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

Clinical Cancer Research 2019 July 1 [Link] Hassan R, Alley E, Kindler H, Antonia SJ, Jahan TM, Honarmand S, Nair N, Whiting C, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy A, Jaffee EM, Coussens LM, Brockstedt DG Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive cancer […]

Comments Off on Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma.

2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.

Anticancer Research 2019 July [Link] Gerogianni I, Pitaraki E, Jagirdar RM, Kouliou O, Giannakou L, Giannopoulos S, Papazoglou E, Hatzoglou C, Gourgoulianis KI, Zarogiannis SG Abstract BACKGROUND/AIM: Malignant pleural mesothelioma (MPM) is a therapy-resistant neoplasm of the pleura. Standard chemotherapy consists of a combination of cisplatin (CPDD) and pemetrexed (PEM). The aim of this study […]

Comments Off on 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.

miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.

Non-coding RNA 2019 June 17 [Link] Kresoja-Rakic J, Szpechcinski A, Kirschner MB, Ronner M, Minatel B, Martinez VD, Lam WL, Weder W, Stahel R, Früh M, Cerciello F, Felley-Bosco E Abstract Combining neo-adjuvant chemotherapy and surgery is part of multimodality treatment of malignant pleural mesothelioma (MPM), but not all patients benefit from this approach. In […]

Comments Off on miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery.

Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma.

Molecular Carcinogenesis 2019 June 19 [Link] Follo C, Cheng Y, Richards WG, Bueno R, Broaddus VC Abstract We have previously shown that nearly half of mesothelioma patients have tumors with low autophagy and that these patients have a significantly worse outcome than those with high autophagy. We hypothesized that autophagy may be beneficial by facilitating […]

Comments Off on Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma.

Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.

Disease Markers 2019 May 2 [Link] Štrbac D, Goričar K, Dolžan V, Kovač V Abstract BACKGROUND: Malignant mesothelioma (MM) is a rare, but fatal disease with few treatment options. The diagnosis and treatment response are challenging in MM. Therefore, the search for novel diagnostic and prognostic biomarkers is ongoing. The aim of our study was […]

Comments Off on Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.